相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
V. S. Hoffmann et al.
LEUKEMIA (2017)
Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents
Frederic Millot et al.
HAEMATOLOGICA (2017)
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
R. Hehlmann et al.
LEUKEMIA (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents
Frederic Millot et al.
HAEMATOLOGICA (2017)
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Tessa L. Holyoake et al.
BLOOD (2017)
Pediatric chronic myeloid leukemia is a unique disease that requires a different approach
Nobuko Hijiya et al.
BLOOD (2016)
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
M. Pfirrmann et al.
LEUKEMIA (2016)
Allogeneic transplantation for CML in the TKI era: striking the right balance
Andrew J. Innes et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis
Sonali Chaudhury et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Impact of Imatinib Adherence on the Cytogenetic Response in Pediatric Chronic Myeloid Leukemia - Chronic Phase
Ranga Raman Ganta et al.
INDIAN JOURNAL OF PEDIATRICS (2016)
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
M. B. Miranda et al.
LEUKEMIA (2016)
The concept of treatment-free remission in chronic myeloid leukemia
S. Saussele et al.
LEUKEMIA (2016)
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
J. L. Steegmann et al.
LEUKEMIA (2016)
Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia
Jill Samis et al.
PEDIATRIC BLOOD & CANCER (2016)
Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia
Delphine Rea
ANNALS OF HEMATOLOGY (2015)
Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?
David Gurrea Salas et al.
ANNALS OF HEMATOLOGY (2015)
Managing children with chronic myeloid leukaemia - response to baccarani
Frederic Millot et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience
Fiorina Giona et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
L. Kalmanti et al.
LEUKEMIA (2015)
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2015)
Managing children with chronic myeloid leukaemia
Michele Baccarani
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Impact of Long-Term Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats
Josephine T. Tauer et al.
PLOS ONE (2015)
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV
Lida Kalmanti et al.
ANNALS OF HEMATOLOGY (2014)
How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia
David M. Ross et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Managing children with chronic myeloid leukaemia (CML) Recommendations for the management of CML in children and young people up to the age of 18 years
Josu de la Fuente et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Growth deceleration in children treated with imatinib for chronic myeloid leukaemia
Frederic Millot et al.
EUROPEAN JOURNAL OF CANCER (2014)
Imatinib Cessation in Children and Adolescents With Chronic Myeloid Leukemia in Chronic Phase
Frederic Millot et al.
PEDIATRIC BLOOD & CANCER (2014)
Sustained Complete Molecular Remission after Imatinib Discontinuation in Children with Chronic Myeloid Leukemia
Olga Moser et al.
PEDIATRIC BLOOD & CANCER (2014)
Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
Vijay Gandhi Linga et al.
SOUTH ASIAN JOURNAL OF CANCER (2014)
Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium
C. Michel Zwaan et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis
Karthik R. Narayanan et al.
PEDIATRIC BLOOD & CANCER (2013)
Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate
K. C. Lakshmaiah et al.
LEUKEMIA & LYMPHOMA (2012)
Imatinib has adverse effect on growth in children with chronic myeloid leukemia
Deepak Bansal et al.
PEDIATRIC BLOOD & CANCER (2012)
Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial
Frederic Millot et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid Leukemia
Haruko Shima et al.
JOURNAL OF PEDIATRICS (2011)
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
E. Jabbour et al.
LEUKEMIA (2011)
Higher Dose Imatinib for Children With De Novo Chronic Phase Chronic Myelogenous Leukemia: A Report From the Children's Oncology Group
Martin A. Champagne et al.
PEDIATRIC BLOOD & CANCER (2011)
Dysregulation of bone remodeling by imatinib mesylate
Kate Vandyke et al.
BLOOD (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults
Divya Menon-Andersen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Allogeneic Stem Cell Transplantation for Pediatric and Adolescent Patients with CML: Results from the Prospective Trial CML-paed I
M. Suttorp et al.
KLINISCHE PADIATRIE (2009)
Imatinib mesylate causes growth plate closure in vivo
K. Vandyke et al.
LEUKEMIA (2009)
Harmonization of molecular monitoring of CML therapy in Europe
M. C. Mueller et al.
LEUKEMIA (2009)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford et al.
BLOOD (2008)
Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis
Hugues de Lavallade et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms
Susannah O'Sullivan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study
MA Champagne et al.
BLOOD (2004)
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia
J Cortes et al.
CANCER (2003)
Stem cell transplantation for chronic myeloid leukemia in children
K Cwynarski et al.
BLOOD (2003)
Practical management of patients with chronic myeloid leukemia receiving imatinib
MWN Deininger et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Quality assurance in RT-PCR-based BCR/ABL diagnostics -: results of an interlaboratory test and a standardization approach
T Burmeister et al.
LEUKEMIA (2000)
分享论文
